You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA29
  • Published:  26 September 2001
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe

The report attempts to assess whether fludarabine has greater effects on patients with CLL than other commonly used treatments.

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe
25 September 2001
(126.34 Kb 36 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 30 March 2010

Back to top